

Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Jeayeon Park^{ORCID}, Su Jong Yu^{ORCID}

Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Received Nov 29, 2024
Revised Jan 4, 2025
Accepted Jan 7, 2025

Corresponding author

Su Jong Yu
Department of Internal Medicine and
Liver Research Institute, Seoul National
University Hospital, Seoul National
University College of Medicine, 101
Daehak-ro, Jongno-gu, Seoul 03080,
Korea
E-mail: ydoctor2@snu.ac.kr

Keywords

Hepatocellular carcinoma; Immune
checkpoint inhibitors; Liver
transplantation; Portal vein; Therapeutic
chemoembolization

Hepatocellular carcinoma with portal vein tumor thrombosis presents a significant therapeutic challenge due to its poor prognosis and limited treatment options. This review thoroughly examines diagnostic methods, including imaging techniques and classification systems such as the Japanese Vp and Cheng's classifications, to aid in clinical decision-making. Treatment strategies encompass liver resection and liver transplantation, particularly living donor liver transplantation after successful downstaging, which have shown potential benefits in selected cases. Locoregional therapies, including hepatic arterial infusion chemotherapy, transarterial chemoembolization, transarterial radioembolization, and external beam radiation therapy, remain vital components of treatment. Recent advancements in systemic therapies, such as sorafenib, lenvatinib, and immune checkpoint inhibitors (e.g., atezolizumab plus bevacizumab) have demonstrated improvements in overall survival and progression-free survival. These developments underscore the importance of a multidisciplinary and personalized approach to improve outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis.

Introduction

Background

In recent years, treatment strategies for hepatocellular carcinoma (HCC) have significantly advanced, incorporating locoregional therapies, surgical resection, liver transplantation (LT), and systemic therapies, including immunotherapy [1–3]. Despite these advancements, portal vein tumor thrombosis (PVTT) continues to pose a major challenge in the treatment of HCC. It represents a critical prognostic factor associated with advanced disease, limited therapeutic options, and poor clinical outcomes [4–6].

The American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and groups in the Asia-Pacific region have published region-specific guidelines for treating HCC with PVTT. These guidelines account for differences in clinical practices, resource availability, and patient characteristics [7–11]. Despite these efforts, a consensus on the best treatment approach has yet to be reached, making the management of HCC with PVTT a significant clinical challenge.

Objectives

This review comprehensively summarizes and analyzes treatment strategies for HCC with PVTT. By integrating the latest research evidence and clinical insights, this article provides guidance on identifying the most optimal treatment strategies for HCC with PVTT in real-world clinical settings.

Ethics statement

As this study is a literature review, it did not require institutional review board approval or individual consent.

Diagnosis and classification of portal vein tumor thrombosis

PVTT is the most prevalent type of macrovascular invasion (MVI) in HCC, with its occurrence at diagnosis ranging from 10% to over 40% [5,12,13]. It can be identified via imaging techniques, particularly on three-phase contrast-enhanced CT scans, where it presents as solid lesions within the portal vein across all phases. These lesions are marked by contrast enhancement during the arterial phase and subsequent washout in the portal venous phase [14]. In contrast, portal vein thrombosis (PVT), often resulting from complications related to cirrhosis or splenectomy, does not show arterial phase enhancement and can be managed with anticoagulant therapy. Thus, accurately differentiating PVTT from PVT is crucial [15]. Another diagnostic tool, ^{18}F -fluorodeoxyglucose (FDG) positron emission tomography/CT, has proven highly effective in distinguishing between malignant and benign thrombi. Malignant thrombi show moderate to high FDG uptake, unlike their benign counterparts [16,17]. The non-invasive diagnostic criteria for differentiating PVTT from PVT, referred to as A-VENA, rely on the presence of three or more indicators: alpha-fetoprotein levels exceeding 1,000 ng/dL, venous expansion, thrombus enhancement, neovascularity, and proximity to HCC [18].

Two widely used systems for assessing the extent of PVTT are the Japanese Vp classification [19] and Cheng's classification, as illustrated in Fig. 1 [20]. The VP classification divides the extent of tumor thrombus in the portal vein into four levels: Vp1, which involves the segmental branches of the portal vein; Vp2, affecting the second-order branches; Vp3, involving the first-order branches; and Vp4, which affects the main trunk of the portal vein and/or the contralateral branch. Cheng's classification also delineates four grades: type I, where the tumor thrombus is located in the segmental or sectoral branches of the portal vein or higher; type II, involving the right or left portal vein; type III, affecting the main portal vein; and type IV, involving the superior mesenteric vein.

Treatment options for hepatocellular carcinoma with portal vein tumor thrombosis

The current evidence-based treatment algorithms for HCC patients with PVTT are presented in Fig. 2.

Liver resection

Liver resection is a curative treatment for patients with HCC and, according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is considered feasible only in early-stage HCC (BCLC stage 0 or A). The presence of PVTT, regardless of tumor size or extent, is classified




Fig. 1. Classification of portal vein tumor thrombosis in hepatocellular carcinoma. RPV, right portal vein; LPV, left portal vein; SMV, superior mesenteric vein.




Fig. 2. Current treatment algorithm for hepatocellular carcinoma patients with portal vein tumor thrombosis. HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; TACE, transarterial chemoembolization; RT, radiation therapy; HAIC, hepatic artery infusion chemotherapy; TARE, transarterial radioembolization.

as BCLC stage C, making liver resection contraindicated [21]. However, in the Asia-Pacific region, liver resection is performed for selected patients outside the BCLC staging system, with several studies demonstrating moderately favorable outcomes. Retrospective analyses have shown that liver resection significantly improves overall survival (OS) in patients with HCC and PVTT, particularly in those with Child-Pugh class A liver function, except in cases involving Vp4 PVTT [22]. A systematic review of 29 studies found that the median OS was longer in patients undergoing liver resection compared to those receiving systemic therapy. The location and extent of PVTT were critical factors influencing survival outcomes, with patients exhibiting distal portal vein branch invasion achieving a 5-year survival rate of 45%, while those with main trunk invasion had survival rates of less than 15% [23]. Clinical guidelines in Korea recommend liver resection for HCC patients with PVTT if the main portal trunk is not involved and liver function is well-preserved [8]. Similarly, Japanese guidelines permit liver resection in cases of portal vein invasion up to the first branch (Vp1–[3]) [9]. In China, liver resection is advised for patients with Child-Pugh class A liver function, PVTT types I or II, and an ECOG performance status of 0–1. Patients with type III PVTT are also considered eligible for liver resection either directly or after tumor downstaging through radiotherapy [7].

Liver transplantation

PVTT has traditionally been viewed as an absolute contraindication due to its strong association with high recurrence rates and poor prognosis [24,25]. Additionally, the use of deceased donor LT in managing HCC with PVTT is limited by the scarcity of available donor organs. However, advancements in surgical techniques have led to an increased adoption of living donor LT for patients with HCC and PVTT. With improvements in locoregional therapies for HCC with PVTT, LT following successful downstaging has emerged as a key area of interest. Retrospective analyses indicate that patients with segmental PVTT who underwent living donor LT experienced significantly better OS and disease-free survival (DFS) rates than those with lobar PVTT [26]. Similarly, studies involving patients with major vascular invasion who underwent downstaging using 3D conformal radiation therapy (RT) and transarterial chemoembolization (TACE) prior to LT showed significantly higher 3-year DFS and OS rates for those meeting the Milan criteria than those who did not [26].

Hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy (HAIC) is a commonly used treatment for advanced HCC. This method involves delivering chemotherapeutic agents such as platinum/oxaliplatin and 5-fluorouracil directly into intrahepatic tumor lesions via a catheter or pump. HAIC is recommended for HCC patients who have major portal vascular invasion and Child-Pugh A liver function but are not eligible for hepatectomy, radiofrequency ablation, TACE, or systemic therapy [9]. A meta-analysis of six studies demonstrated that HAIC outperformed sorafenib in HCC patients with PVTT, particularly in those with types III–IV PVTT. HAIC showed better OS, progression-free survival (PFS), and disease control rate, although it was associated with higher rates of myelosuppression [27]. Additionally, a phase III randomized controlled trial (SILIUS study) from Japan reported that combining HAIC with sorafenib improved OS compared to sorafenib alone in patients with Vp4 PVTT. However, no significant difference in median OS was observed for patients with Vp1–3 PVTT [28]. Furthermore, a study comparing TACE-HAIC combined with targeted therapy and immunotherapy to TACE alone in HCC patients with PVTT showed superior outcomes for the combination group, with significantly better OS [29].

Transarterial chemoembolization

TACE is a widely utilized technique for managing unresectable HCC with PVTT [30]. It is particularly considered for patients with good liver function and sufficient collateral circulation around the obstructed portal vein [31,32]. In patients with type III/IV PVTT, its application remains controversial due to the associated risks of liver infarction and hepatic failure, although TACE has shown potential to extend OS [33]. A meta-analysis of 13 trials involving 1,933 patients was conducted to assess the safety and efficacy of TACE in managing HCC with PVTT. The study found that patients with PVTT in the main portal vein trunk had significantly worse survival rates compared to those with segmental PVTT ($P<0.001$) [34]. The limited effectiveness of TACE as a standalone therapy highlights the importance of combining it with other treatment modalities to improve OS in patients with HCC and PVTT [35]. A study comparing the effectiveness of TACE combined with RT against sorafenib therapy demonstrated that the combination therapy achieved a median OS of 12.8 months, significantly higher than the 10.0 months observed with sorafenib alone ($P=0.04$) [36]. An analysis of 25 studies, including 2,577 patients, revealed that combining TACE with RT significantly improved the 1-year survival rate compared to TACE alone [37]. This finding suggests that the TACE and RT combination could serve as a primary treatment approach for HCC patients with MVI [38]. The median OS was significantly longer in the TACE and sorafenib combination group compared to the sorafenib monotherapy group (8.9 vs. 5.9 months, $P=0.009$), with improved OS observed in patients with MVI (hazard ratio [HR] 0.64; 95% CI 0.44–0.92; $P=0.02$) [39]. The clinical outcomes of combining TACE with immune checkpoint inhibitors are still limited, and further research is needed to establish their efficacy and potential benefits.

Transarterial radioembolization

Transarterial radioembolization (TARE) with yttrium-90 microspheres is recognized as an effective treatment option for HCC patients with PVTT, offering a unique approach that combines microembolization with targeted radiotherapy [40]. Two phase III studies found no significant difference in OS between TARE and sorafenib [41,42]. However, a meta-analysis of 17 trials revealed higher 6-month and 1-year OS rates in the TARE group (76% and 47%, respectively) compared to the sorafenib group (54% and 24%) [43]. A case report suggested that concurrent TARE and combination therapy with atezolizumab plus bevacizumab could be an effective and safe treatment regimen for patients with infiltrative HCC and PVTT [44]. Nonetheless, retrospective studies and clinical trials are warranted to validate these findings. Existing evidence suggests that TARE is an effective treatment for HCC patients with PVTT, with response rates ranging from 50% to 75% and a median survival time of approximately 10 months [40]. Although internal radiotherapy is a more invasive treatment, it delivers a sustained high dose of radiation to PVTT while sparing nearby normal liver tissue, making it particularly beneficial for patients with malignant portal vein stenosis or occlusion [45].

External beam radiation therapy

For patients with unresectable HCC and all types of PVTT, RT is recommended, targeting both the primary tumor and PVTT lesions. Advances in technologies such as three-dimensional conformal RT, intensity-modulated RT, and stereotactic body RT (SBRT) have enabled higher radiation doses to be delivered to the targeted areas while protecting adjacent normal tissues [46,47]. Target localization for RT often utilizes CT and magnetic resonance imaging fusion based on lipiodol deposition following TACE [48]. The optimal irradiation area remains a topic

of debate and should be personalized. In cases where the hepatic lesion is small and PVTT is nearby, both the tumor and PVTT can be targeted simultaneously. For larger tumors or distant PVTT, irradiation may be focused exclusively on the PVTT [49]. Studies have shown that RT, either as a standalone treatment or combined with other modalities, improves survival and quality of life in these patients. When comparing sorafenib and RT in HCC patients with Vp3-4 PVTT, RT showed a significantly better median OS after propensity score matching (10.9 vs. 4.8 months; $P=0.025$) [50]. Similarly, in a Korean multicenter retrospective cohort study using propensity score matching, RT demonstrated an improved response rate in HCC patients with PVTT [51]. The efficacy of SBRT combined with sorafenib compared to SBRT alone was retrospectively assessed in patients with HCC and PVTT [52]. The findings demonstrated that the combination therapy resulted in longer median PFS (6 vs. 3 months) and median OS (12.5 vs. 7 months) than SBRT alone, although these differences were not statistically significant.

Systemic therapy

Atezolizumab with bevacizumab

The combination of atezolizumab and bevacizumab has been established as a first-line systemic therapy for unresectable HCC, as demonstrated by its superiority over sorafenib in the IMbrave150 trial [53]. This regimen has demonstrated a strong antitumor effect in advanced HCC with Vp4 PVTT and is associated with minimal impact on hepatic function in the early stages of treatment [54], along with a favorable initial response [55]. Updated efficacy and safety data from the IMbrave150 trial show that patients with MVI experienced improved median OS and PFS when treated with atezolizumab plus bevacizumab compared to those treated with sorafenib (Tables 1, 2) [56]. Additionally, therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib have been found comparable for managing HCC with PVTT [57]. A multicenter cohort study conducted in South Korea demonstrated that atezolizumab plus bevacizumab achieved superior 1-year survival and PFS rates compared to TACE plus RT in HCC patients with PVTT and no metastasis. These findings suggest that atezolizumab plus bevacizumab should be considered a primary treatment option for this patient group [58].

Other immune checkpoint inhibitors

Subgroup analyses from multiple clinical trials of immune checkpoint inhibitors have assessed clinical outcomes in patients with HCC and MVI (Tables 1, 2). The HIMALAYA trial evaluated the clinical outcomes of combining tremelimumab with durvalumab versus using sorafenib alone. It showed a trend toward improved OS in patients with HCC and MVI, although the results did not reach statistical significance [59]. The CARES-310 trial compared camrelizumab plus rivoceranib with sorafenib and demonstrated statistically significant improvements in both OS and PFS for patients with HCC and MVI [60]. In the context of second-line treatment, the KEYNOTE-240 trial, which compared pembrolizumab to placebo, was the sole study to specifically analyze clinical outcomes in patients with HCC and MVI. Despite not achieving statistical significance, pembrolizumab exhibited a trend toward better OS and PFS compared to placebo [61]. Notably, unlike the IMbrave150 trial, these clinical trials excluded patients with Vp4 or type III/IV PVTT.

Sorafenib

Sorafenib, an orally administered multi-kinase inhibitor, was the first targeted therapy approved for HCC patients with PVTT, based on the results of two phase III randomized, double-

Table 1. Overall survival in clinical trials of first-line or second-line systemic therapy for unresectable HCC with PVTT

Author/trial (year)	Phase	Treatment	Number of patients MVI/All	Median OS in all patients	HR (95% CI) in all patients	Median OS with MVI	HR (95% CI) with MVI	
First-line								
Cheng et al. [56] IMbrave150 updated (2022)	III	Atezolizumab plus bevacizumab	129/336	19.2 months (17.0–23.7)	0.66 (0.52–0.85)	14.2 months (11.0–19.4)	0.68 (0.47–0.98)	
		Sorafenib	71/165	13.4 (11.4–16.9)	Reference	9.7 months (6.1–13.1)	Reference	
Abou-Alfa et al. [59] HIMALAYA (2022)	III	Tremelimumab plus durvalumab	103/393	16.4 months (14.2–19.6)	0.78 (0.65–0.93)	-	0.78 (0.57–1.07)	Exclude Vp4/Type III/IV
		Durvalumab	94/389	16.6 months (14.1–19.1)	0.86 (0.73–1.03)	-	0.85 (0.62–1.17)	
		Sorafenib	100/389	13.8 months (12.3–16.1)	Reference	-	Reference	
Qin et al. [60] CARES-310 (2023)	III	Camrelizumab plus rivoceranib	40/272	22.1 months (19.1–27.2)	0.62 (0.49–0.80)	-	0.56 (0.32–0.99)	Exclude Vp4/Type III/IV
		Sorafenib	52/271	15.2 months (13.0–18.5)	Reference	-	Reference	
Second-line								
Finn et al. [61] KEYNOTE 240 (2020)	III	Pembrolizumab	36/278	13.9 months (11.6–16.0)	0.78 (0.61–0.998)	-	0.57 (0.29–1.13)	Exclude Vp4/Type III/IV
		Placebo	16/135	10.6 months (8.3–13.5)	Reference	-	Reference	

HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; MVI, macrovascular invasion; OS, overall survival; HR, hazard ratio.

Table 2. Progression-free survival in clinical trials of first-line or second-line systemic therapy for unresectable HCC with PVTT

Author/trial (year)	Phase	Treatment	Number of patients MVI/All	Median PFS in all patients	HR (95% CI) in all patients	Median PFS with MVI	HR (95% CI) with MVI	
First-line								
Cheng et al. [56] IMbrave150 updated (2022)	III	Atezolizumab plus bevacizumab	129/336	6.9 months (5.7–8.6)	0.65 (0.53–0.81)	6.7 months (5.4–8.3)	0.59 (0.43–0.83)	
		Sorafenib	71/165	4.3 months (4.0–5.6)	Reference	4.2 months (2.8–5.3)	Reference	
Abou-Alfa et al. [59] HIMALAYA (2022)	III	Tremelimumab plus durvalumab	103/393	3.8 months (3.7–5.3)	0.90 (0.77–1.05)	-	-	Exclude Vp4/Type III/IV
		Durvalumab	94/389	3.7 months (3.2–3.8)	1.02 (0.88–1.19)	-	-	
		Sorafenib	100/389	4.1 months (3.8–5.5)	Reference	-	-	
Qin et al. [60] CARES-310 (2023)	III	Camrelizumab plus rivoceranib	40/272	5.6 months (5.5–6.3)	0.52 (0.41–0.65)	-	0.55 (0.44–0.70)	Exclude Vp4/Type III/IV
		Sorafenib	52/271	3.7 months (2.8–3.7)	Reference	-	Reference	
Second-line								
Finn et al. [61] KEYNOTE 240 (2020)	III	Pembrolizumab	36/278	3.0 months (2.8–4.1)	0.72 (0.57–0.90)	-	0.80 (0.42–1.51)	Exclude Vp4/Type III/IV
		placebo	16/135	2.8 months (1.6–3.0)	Reference	-	Reference	

HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; MVI, macrovascular invasion; PFS, progression-free survival; HR, hazard ratio.

blind, placebo-controlled trials [62,63]. The SHARP trial reported a median survival time of 10.7 months [63], whereas an Asia-Pacific study reported a median survival time of 6.5 months [10]. However, real-world outcomes may be less favorable due to potential selection bias in clinical trials [10,64]. The phase III STAH study suggested that combining sorafenib with TACE might improve OS in HCC patients with PVTT compared to sorafenib alone, although the difference was not statistically significant [65]. Additionally, a randomized controlled trial involving 99 patients with HCC, cirrhosis, and PVTT found that combining sorafenib with radiofrequency ablation significantly improved OS rates compared to sorafenib monotherapy [66].

Lenvatinib

Lenvatinib, a multi-kinase inhibitor with antiangiogenic properties, has been shown to be effective in treating advanced HCC, as evidenced by a randomized phase III noninferiority trial [67]. In comparison to sorafenib, lenvatinib not only demonstrated similar median survival times but also achieved a higher objective response rate and longer PFS [67]. Additionally, a case report highlighted that after 11 months of treatment with lenvatinib for advanced HCC with PVTT, the PVTT became undetectable, and the vascularization of the primary tumor had resolved [68].

Conclusion

The management of HCC with PVTT requires a multidisciplinary approach that incorporates locoregional therapies, systemic treatments, and surgical interventions, all tailored to the specific clinical context of each patient. Recent advancements, such as immune checkpoint inhibitors and combination strategies like TACE with RT, have shown considerable promise in enhancing clinical outcomes. These developments highlight the critical need for personalized treatment strategies to navigate the complexities and improve the prognosis for this high-risk population.

ORCID

Jeayeon Park: <https://orcid.org/0000-0003-1155-0588>

Su Jong Yu: <https://orcid.org/0000-0001-8888-7977>

Authors' contributions

Project administration: Park J, Yu SJ

Conceptualization: Park J, Yu SJ

Methodology & data curation: Park J, Yu SJ

Funding acquisition: not applicable

Writing – original draft: Park J, Yu SJ

Writing – review & editing: Park J, Yu SJ

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Funding

Not applicable.

Data availability

Not applicable.

Acknowledgments

Not applicable.

Supplementary materials

Not applicable.

References

1. Teufel A, Kudo M, Qian Y, Daza J, Rodriguez I, Reissfelder C, et al. Current trends and advancements in the management of hepatocellular carcinoma. *Dig Dis* 2024;42(4):349-360.
<https://doi.org/10.1159/000538815>
2. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, et al. Recent advances in the management of hepatocellular carcinoma. *Clin Mol Hepatol* 2024;30(1):1-15.
<https://doi.org/10.3350/cmh.2023.0125>
3. Yang X, Yang C, Zhang S, Geng H, Zhu AX, Bernards R, et al. Precision treatment in advanced hepatocellular carcinoma. *Cancer Cell* 2024;42(2):180-197.
<https://doi.org/10.1016/j.ccell.2024.01.007>
4. Chan SL, Mo FKF, Johnson PJ, Liem GS, Chan TC, Poon MC, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. *J Gastroenterol Hepatol* 2011;26(2):340-347.
<https://doi.org/10.1111/j.1440-1746.2010.06329.x>
5. Llovet JM, Bustamante J, Castells A, Vilana R, Del Carmen Ayuso M, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999;29(1):62-67.
<https://doi.org/10.1002/hep.510290145>
6. Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadehd A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. *Thromb Res* 2008;122(3):299-306.
<https://doi.org/10.1016/j.thromres.2007.10.009>
7. Sun J, Guo R, Bi X, Wu M, Tang Z, Lau WY, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition). *Liver Cancer* 2022;11(4):315-328.
<https://doi.org/10.1159/000523997>
8. Korean Liver Cancer Association, National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. *Korean J Radiol* 2022;23(12):1126-1240.
<https://doi.org/10.3348/kjr.2022.0822>
9. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. *Liver Cancer* 2021;10(3):181-223.
<https://doi.org/10.1159/000514174>
10. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018;69(1):182-236.
<https://doi.org/10.1016/j.jhep.2018.03.019>

11. Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. *Hepatology* 2018;67(1):422-435.
<https://doi.org/10.1002/hep.29486>
12. Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. *World J Gastroenterol* 2015;21(12):3462-3471.
<https://doi.org/10.3748/wjg.v21.i12.3462>
13. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. *World J Gastroenterol* 2006;12(47):7561-7567.
<https://doi.org/10.3748/wjg.v12.i47.7561>
14. Hennemig T, Venkatesh SK. Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma. *World J Gastroenterol* 2016;22(1):205-220.
<https://doi.org/10.3748/wjg.v22.i1.205>
15. Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Maurizio LD, et al. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. *World J Gastroenterol* 2010;16(2):143-155.
<https://doi.org/10.3748/wjg.v16.i2.143>
16. Agarwal KK, Shah D, Shah N, Mayank M. Differentiation of malignant thrombus from bland thrombus of the portal vein in patient with hepatocellular carcinoma on 18F-FDG PET CT. *Clin Nucl Med* 2017;42(11):e472-e474.
<https://doi.org/10.1097/RLU.0000000000001840>
17. Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. *Abdom Radiol* 2019;44(7):2430-2435.
<https://doi.org/10.1007/s00261-019-01997-2>
18. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N, et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. *Liver Transpl* 2019;25(2):207-216.
<https://doi.org/10.1002/lt.25345>
19. Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. *Surg Oncol Clin N Am* 2003;12(1):65-75.
[https://doi.org/10.1016/s1055-3207\(02\)00082-0](https://doi.org/10.1016/s1055-3207(02)00082-0)
20. Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Guanghui D, et al. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. *Hepato-gastroenterology* 2007;54(74):499-502.
21. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol* 2022;76(3):681-693.
<https://doi.org/10.1016/j.jhep.2021.11.018>
22. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol* 2016;65(5):938-943.
<https://doi.org/10.1016/j.jhep.2016.05.044>
23. Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, et al. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. *Eur J Surg Oncol* 2018;44(2):195-208.

- <https://doi.org/10.1016/j.ejso.2017.11.022>
24. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009;10(1):35-43.
[https://doi.org/10.1016/S1470-2045\(08\)70284-5](https://doi.org/10.1016/S1470-2045(08)70284-5)
 25. Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. *Gut* 2016;65(6):1035-1041.
<https://doi.org/10.1136/gutjnl-2014-308513>
 26. Choi HJ, Kim DG, Na GH, Hong TH, Bae SH, You YK, et al. The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation. *Liver Transpl* 2017;23(8):1023-1031.
<https://doi.org/10.1002/lt.24782>
 27. Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. *J Gastroenterol Hepatol* 2020;35(8):1277-1287.
<https://doi.org/10.1111/jgh.15010>
 28. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. *Lancet Gastroenterol Hepatol* 2018;3(6):424-432.
[https://doi.org/10.1016/S2468-1253\(18\)30078-5](https://doi.org/10.1016/S2468-1253(18)30078-5)
 29. Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. *Int J Surg* 2023;109(5):1222-1230.
<https://doi.org/10.1097/JS9.0000000000000256>
 30. Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. *BMC Gastroenterol* 2013;13:60.
<https://doi.org/10.1186/1471-230X-13-60>
 31. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. *Radiology* 2011;258(2):627-634.
<https://doi.org/10.1148/radiol.10101058>
 32. Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. *Radiographics* 2005;25(suppl_1):S25-S39.
<https://doi.org/10.1148/rg.25si055508>
 33. Chan SL, Chong CCN, Chan AWH, Poon DMC, Chok KSH. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. *World J Gastroenterol* 2016;22(32):7289-7300.
<https://doi.org/10.3748/wjg.v22.i32.7289>
 34. Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. *HPB* 2017;19(8):659-666.
<https://doi.org/10.1016/j.hpb.2017.04.016>

35. Luo F, Li M, Ding J, Zheng S. The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. *Front Oncol* 2021;11:635731.
<https://doi.org/10.3389/fonc.2021.635731>
36. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. *JAMA Oncol* 2018;4(5):661-669.
<https://doi.org/10.1001/jamaoncol.2017.5847>
37. Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. *JAMA Oncol* 2015;1(6):756-765.
<https://doi.org/10.1001/jamaoncol.2015.2189>
38. Jin S, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, et al. Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. *J Liver Cancer* 2023;23(1):177-188.
<https://doi.org/10.17998/jlc.2023.03.04>
39. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. *Radiology* 2013;269(2):603-611.
<https://doi.org/10.1148/radiol.13130150>
40. Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. *Semin Liver Dis* 2018;38(03):242-251.
<https://doi.org/10.1055/s-0038-1666805>
41. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SiRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. *J Clin Oncol* 2018;36(19):1913-1921.
<https://doi.org/10.1200/JCO.2017.76.0892>
42. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol* 2017;18(12):1624-1636.
[https://doi.org/10.1016/S1470-2045\(17\)30683-6](https://doi.org/10.1016/S1470-2045(17)30683-6)
43. Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. *Korean J Radiol* 2019;20(3):385-398.
<https://doi.org/10.3348/kjr.2018.0496>
44. Park MK, Yu SJ. Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report. *J Liver Cancer* 2022;22(1):69-74.
<https://doi.org/10.17998/jlc.2022.03.09>
45. Tan Z, Lu J, Zhu G, Chen L, Wang Y, Zhang Q, et al. Portal vein irradiation stent plus chemoembolization versus external radiotherapy plus chemoembolization in hepatocellular carcinoma with portal vein tumour thrombus: a retrospective study. *Cardiovasc Intervent Radiol* 2021;44(9):1414-1422.
<https://doi.org/10.1007/s00270-021-02889-z>

46. Hsieh CH, Liu CY, Shueng PW, Chong NS, Chen CJ, Chen MJ, et al. Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma. *Radiat Oncol* 2010;5:40.
<https://doi.org/10.1186/1748-717X-5-40>
47. Kang J, Nie Q, Du R, Zhang L, Zhang J, Li Q, et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. *Mol Clin Oncol* 2014;2(1):43-50.
<https://doi.org/10.3892/mco.2013.196>
48. Wang MH, Ji Y, Zeng ZC, Tang ZY, Fan J, Zhou J, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. *Int J Radiat Oncol Biol Phys* 2010;76(2):467-476.
<https://doi.org/10.1016/j.ijrobp.2009.01.057>
49. Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. *World J Gastroenterol* 2016;22(30):6851-6863.
<https://doi.org/10.3748/wjg.v22.i30.6851>
50. Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. *BMC Gastroenterol* 2014;14:84.
<https://doi.org/10.1186/1471-230X-14-84>
51. Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. *Liver Int* 2017;37(1):90-100.
<https://doi.org/10.1111/liv.13191>
52. Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH, et al. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. *Medicine* 2020;99(13):e19660.
<https://doi.org/10.1097/MD.00000000000019660>
53. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TT, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med* 2020;382(20):1894-1905.
<https://doi.org/10.1056/NEJMoa1915745>
54. Komatsu S, Fujishima Y, Kido M, Kuramitsu K, Goto T, Yanagimoto H, et al. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report. *BMC Gastroenterol* 2021;21(1):470.
<https://doi.org/10.1186/s12876-021-02053-4>
55. Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience. *Cancer Rep* 2022;5(2):e1464.
<https://doi.org/10.1002/cnr2.1464>
56. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol* 2022;76(4):862-873.
<https://doi.org/10.1016/j.jhep.2021.11.030>
57. Park J, Lee YB, Ko Y, Park Y, Shin H, Hur MH, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.

- J Liver Cancer* 2024;24(1):81-91.
<https://doi.org/10.17998/jlc.2023.12.25>
58. Lee SK, Kwon JH, Lee SW, Lee HL, Kim HY, Kim CW, et al. A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis. *Cancers* 2023;15(17):4423.
<https://doi.org/10.3390/cancers15174423>
 59. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *NEJM Evid* 2022;1(8):EVIDoa2100070.
<https://doi.org/10.1056/EVIDoa2100070>
 60. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. *Lancet* 2023;402(10408):1133-1146.
[https://doi.org/10.1016/S0140-6736\(23\)00961-3](https://doi.org/10.1016/S0140-6736(23)00961-3)
 61. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. *J Clin Oncol* 2020;38(3):193-202.
<https://doi.org/10.1200/JCO.19.01307>
 62. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359(4):378-390.
<https://doi.org/10.1056/NEJMoa0708857>
 63. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009;10(1):25-34.
[https://doi.org/10.1016/S1470-2045\(08\)70285-7](https://doi.org/10.1016/S1470-2045(08)70285-7)
 64. Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. *Gut Liver* 2013;7(6):696-703.
<https://doi.org/10.5009/gnl.2013.7.6.696>
 65. Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. *J Hepatol* 2019;70(4):684-691.
<https://doi.org/10.1016/j.jhep.2018.11.029>
 66. Giorgio A, Merola MG, Montesarchio L, Merola F, Santoro B, Coppola C, et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a western randomized controlled trial. *Anticancer Res* 2016;36(11):6179-6183.
<https://doi.org/10.21873/anticancer.11211>
 67. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018;391(10126):1163-1173.
[https://doi.org/10.1016/S0140-6736\(18\)30207-1](https://doi.org/10.1016/S0140-6736(18)30207-1)
 68. Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, et al. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. *Hepatol Res* 2019;49(5):594-599.
<https://doi.org/10.1111/hepr.13294>